ArticleCancer immunology, immunotherapy : CII2025
The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
Chie Kudo-Saito et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.